Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity

BACKGROUND: Tumor mutational burden (TMB) measurement is limited by low tumor purity of samples, which can influence prediction of the immunotherapy response, particularly when using whole-exome sequencing-based TMB (wTMB). This issue could be overcome by targeted panel sequencing-based TMB (pTMB) w...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Tae Hee, Cha, Hongui, Shim, Joon Ho, Lee, Boram, Chung, Jongsuk, Lee, Chung, Kim, Nayoung K D, Choi, Yoon-La, Hwang, Soohyun, Lee, Yoomi, Park, Sehhoon, Jung, Hyun Ae, Kim, Ji-Yeon, Park, Yeon Hee, Sun, Jong-Mu, Ahn, Jin Seok, Ahn, Myung-Ju, Park, Keunchil, Lee, Se-Hoon, Park, Woong-Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7574938/
https://www.ncbi.nlm.nih.gov/pubmed/33077514
http://dx.doi.org/10.1136/jitc-2020-001199

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7574938/
https://www.ncbi.nlm.nih.gov/pubmed/33077514
http://dx.doi.org/10.1136/jitc-2020-001199

Ejemplares similares